Filtered By:
Drug: Rituxan
Countries: Germany Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Myasthenia in adults, children, and adolescents: what's new?
Nervenarzt. 2023 Mar 30. doi: 10.1007/s00115-023-01463-x. Online ahead of print.ABSTRACTTherapy of myasthenia gravis (MG) is increasingly oriented to the patient's antibody status. In addition to symptomatic therapy, steroids, classic long-term immunosuppressive therapies and thymectomy are regularly used. In recent years, new therapeutic approaches have been developed that particularly benefit acetylcholine receptor (AChR) antibody (Abs) positive patients with highly active disease. While the C5 complement inhibitor eculizumab was reserved for treatment-refractory generalized courses of AChR-Abs positive MG, two new drugs...
Source: Der Nervenarzt - March 30, 2023 Category: Neurology Authors: Frauke Stascheit Adela Della Marina Andreas Meisel Source Type: research
Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database
CONCLUSION: DLBCL-associated mortality is still high, especially in relapsed patients and in the elderly. Therefore, there is a high medical need for new effective treatments that can improve survival outcomes in DLBCL patients.PMID:36871091 | DOI:10.1007/s00432-023-04660-y
Source: Cell Research - March 4, 2023 Category: Cytology Authors: Peter Borchmann Jan-Michel Heger J örg Mahlich Michael S Papadimitrious Sybille Riou Barbara Werner Source Type: research
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
The objective is to demonstrate superiority of a de-escalated and optimised remission induction treatment strategy, followed by HCT-ASCT. Randomization (1:1) will be performed after completion of all screening procedures. Patients in Arm A (control treatment) will receive 4 cycles of MATRix. Patients in Arm B (experimental treatment) will receive a pre-phase (R/HD-MTX), followed by 2 cycles of MATRix. Patients in both arms achieving PR or better will proceed to HCT-ASCT (BCNU, thiotepa). The primary endpoint of the study is event-free-survival (EFS), defined as time from randomization to premature end of treatment due to a...
Source: Cancer Control - September 10, 2022 Category: Cancer & Oncology Authors: Julia Wendler Christopher P Fox Elke Valk Cora Steinheber Heidi Fricker Lisa K Isbell Simone Neumaier Jessica Okosun Florian Scherer Gabriele Ihorst Kate Cwynarski Elisabeth Schorb Gerald Illerhaus Source Type: research
Bullous Autoimmune Dermatoses
CONCLUSION: The early recognition and precise diagnostic evaluation of bullous autoimmune dermatoses now enables improved, often interdisciplinary treatment, in accordance with the available guidelines. Current research projects are focused on new treatment approaches, an improved understanding of the underlying pathophysiology, and further refinements of diagnostic techniques.PMID:34369370 | DOI:10.3238/arztebl.m2021.0136
Source: Deutsches Arzteblatt International - August 9, 2021 Category: General Medicine Authors: Nina van Beek Detlef Zillikens Enno Schmidt Source Type: research
Global research publications on systemic use of off-label and unlicensed drugs: A bibliometric analysis (1990-2020)
CONCLUSIONS: Research activity on off-label drug use has witnessed a general increase in the past two decades. The major research theme was off-label drug use in hospitalized children/pediatrics/neonates. The USA and certain European countries made a major contribution to this field.PMID:34275912 | DOI:10.3233/JRS-210012
Source: International Journal of Risk and Safety in Medicine - July 19, 2021 Category: Drugs & Pharmacology Authors: Waleed M Sweileh Source Type: research
